These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 27770109)

  • 1. The Application of Paraphenylenediamine Staining for Assessment of Phospholipidosis.
    Shirai N; Geoly FJ; Bobrowski WF; Okerberg C
    Toxicol Pathol; 2016 Dec; 44(8):1160-1165. PubMed ID: 27770109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytochemical demonstration of increased phospholipid content in cell membranes in chlorphentermine-induced phospholipidosis.
    Coulombe PA; Bendayan M
    J Histochem Cytochem; 1989 Feb; 37(2):139-47. PubMed ID: 2911004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An immunohistochemical approach to differentiate hepatic lipidosis from hepatic phospholipidosis in rats.
    Obert LA; Sobocinski GP; Bobrowski WF; Metz AL; Rolsma MD; Altrogge DM; Dunstan RW
    Toxicol Pathol; 2007 Aug; 35(5):728-34. PubMed ID: 17763287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Immunohistochemical Investigation of Renal Phospholipidosis and Toxicity in Rats.
    Ma JY; Snook S; Garrovillo S; Johnson C; La D
    Int J Toxicol; 2017; 36(5):386-394. PubMed ID: 28820006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imaging Mass Microscopy of Kidneys from Azithromycin-Treated Rats with Phospholipidosis.
    Sakurai T; Kamio K; Sasaki K; Nishimoto T; Yamaguchi JI; Sasaki M; Tsutsumi S
    Am J Pathol; 2018 Sep; 188(9):1993-2003. PubMed ID: 29981744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A clinical flow cytometric biomarker strategy: validation of peripheral leukocyte phospholipidosis using Nile red.
    Halstead BW; Zwickl CM; Morgan RE; Monteith DK; Thomas CE; Bowers RK; Berridge BR
    J Appl Toxicol; 2006; 26(2):169-77. PubMed ID: 16278808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemistry of LAMP-2 and adipophilin for phospholipidosis in liver and kidney in ketoconazole-treated mice.
    Asaoka Y; Togashi Y; Imura N; Sai T; Miyoshi T; Miyamoto Y
    Exp Toxicol Pathol; 2013 Sep; 65(6):817-23. PubMed ID: 23276623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell-based fluorescence assay for evaluation of new-drugs potential for phospholipidosis in an early stage of drug development.
    Fujimura H; Dekura E; Kurabe M; Shimazu N; Koitabashi M; Toriumi W
    Exp Toxicol Pathol; 2007 Aug; 58(6):375-82. PubMed ID: 17408938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of phospholipidosis induction: a cell-based assay in high-throughput and high-content format.
    Shahane SA; Huang R; Gerhold D; Baxa U; Austin CP; Xia M
    J Biomol Screen; 2014 Jan; 19(1):66-76. PubMed ID: 24003057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lead-induced phospholipidosis and cholesterogenesis in rat tissues.
    Ademuyiwa O; Agarwal R; Chandra R; Behari JR
    Chem Biol Interact; 2009 May; 179(2-3):314-20. PubMed ID: 19056365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system.
    Sawada H; Takami K; Asahi S
    Toxicol Sci; 2005 Feb; 83(2):282-92. PubMed ID: 15342952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluorescence studies on binding of amphiphilic drugs to isolated lamellar bodies: relevance to phospholipidosis.
    Joshi UM; Rao P; Kodavanti S; Lockard VG; Mehendale HM
    Biochim Biophys Acta; 1989 Aug; 1004(3):309-20. PubMed ID: 2758025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro assays and biomarkers for drug-induced phospholipidosis.
    Monteith DK; Morgan RE; Halstead B
    Expert Opin Drug Metab Toxicol; 2006 Oct; 2(5):687-96. PubMed ID: 17014389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High content screening analysis of phospholipidosis: validation of a 96-well assay with CHO-K1 and HepG2 cells for the prediction of in vivo based phospholipidosis.
    van de Water FM; Havinga J; Ravesloot WT; Horbach GJ; Schoonen WG
    Toxicol In Vitro; 2011 Dec; 25(8):1870-82. PubMed ID: 21651975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug-induced phospholipidosis.
    Anderson N; Borlak J
    FEBS Lett; 2006 Oct; 580(23):5533-40. PubMed ID: 16979167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of physicochemical calculation of pKa and CLogP to predict phospholipidosis-inducing potential: a case study with structurally related piperazines.
    Ploemen JP; Kelder J; Hafmans T; van de Sandt H; van Burgsteden JA; Saleminki PJ; van Esch E
    Exp Toxicol Pathol; 2004 Mar; 55(5):347-55. PubMed ID: 15088636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular biomarkers of phospholipidosis in rat blood and heart after amiodarone treatment.
    Bocchini N; Giantin M; Crivellente F; Ferraresso S; Faustinelli I; Dacasto M; Cristofori P
    J Appl Toxicol; 2015 Jan; 35(1):90-103. PubMed ID: 25580480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phospholipidosis in healthy subjects participating in clinical studies: ultrastructural findings in white blood cells.
    Pospischil A; Walther P; Dingemanse J
    Exp Toxicol Pathol; 2010 Sep; 62(5):567-71. PubMed ID: 19674876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploiting ensemble learning to improve prediction of phospholipidosis inducing potential.
    Nath A; Sahu GK
    J Theor Biol; 2019 Oct; 479():37-47. PubMed ID: 31310757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A cell-based approach for the early assessment of the phospholipidogenic potential in pharmaceutical research and drug development.
    Casartelli A; Bonato M; Cristofori P; Crivellente F; Dal Negro G; Masotto I; Mutinelli C; Valko K; Bonfante V
    Cell Biol Toxicol; 2003 Jun; 19(3):161-76. PubMed ID: 12945744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.